- ¥2400 - 22000
- solarbio
- 中国
- E8340
- 2025年09月06日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
-20°C
- 保质期：
3年
- 英文名：
Elacridar
- 库存：
大量
- 供应商：
solarbio
- CAS号：
143664-11-3
- 规格：
10mg/100mg
| 规格： | 10mg | 产品价格： | ¥2400.0 |
|---|---|---|---|
| 规格： | 100mg | 产品价格： | ¥22000.0 |
依克立达
品牌：Solarbio货号：E8340
别名 : 依克立达;ELACRIDAR (GF120918);N-[4-[2-(6,7-二甲氧基-3,4-二氢-1H-异喹啉-2-基)乙基]苯基]-5-甲氧基-9-氧代-10H-吖啶-4-甲酰胺
英文名称 : Elacridar
CAS : 143664-11-3
分子式 : C34H33N3O5
分子量 : 563.64292
储存条件 : -20°C
纯度 : ＞98%
单位 : 支
Biological Activity:
Elacridar (GF120918; GW0918) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.
Target: P-glycoprotein
In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450 enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in preclinical species and offer additional guidance on preclinical dose regimens likely to produce P-glycoprotein-mediated effects.
Elacridar
Cat.: E8340
Size: 10mg
CAS No.: 143664-11-3
M.Wt: 563.64
Formula:C34H33N3O5
Purity: ＞98%
Solvent & Solubility: 10 mM in DMSO
Storage: -20℃
Biological Activity:
Elacridar (GF120918; GW0918) is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo
as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of
various test molecules.
Target: P-glycoprotein
In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive
protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and
dog plasma. GF120918A did not demonstrate potent inhibition of several human cytochrome P450
enzymes evaluated in vitro, with IC(50) values well above concentrations anticipated to be achieved in
vivo. Together, these data confirm the utility of GF120918A as a tool P-glycoprotein inhibitor in
preclinical species and offer additional guidance on preclinical dose regimens likely to produce
P-glycoprotein-mediated effects.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
